**PERSONAL INFORMATION**

Name: Mohamed Labib Salem

Position: Professor of Immunology

**Tenure Affiliation**: Faculty of Science, Tanta University, Egypt

Tel: +20-040 334-4352 (work); +20-01274272624 (mobile)

FAX: +20-040 335-0804

E-mail: mohamedlabibsalem@yahoo.com

Mohamed.labib@science.tanta.edu.eg

**Prior Affiliation:** Assistant Professer

(2001-2010) Department of Microbiology and Immunology

Medical University of South Carolina, Charleston, SC, USA

843-743-8439

**EDUCATION**

* ***PhD (ImmunoEndocrinology)*** Department of Immunology, Kyushu University, Japan
* ***MSc (Comparative Anatomy):*** Faculty of Science, Tanta University, Egypt
* ***Post-graduate Diploma (Comparative Anatomy):*** Faculty of Science, Tanta University, Egypt
* ***BS (General Zoology)***: Faculty of Science, Tanta University, Egypt

**ACADEMIC POSITIONS**

1. **Professor:** Faculty of Science, Tanta University, Egypt (2010 - Present)
2. **Visiting Professor:** Department of Microbiology and Immunology, Medical University of South Carolina, USA (2012 - 2013)
3. **Assistant Professor:** Department of Surgery, Medical University of South Carolina,

USA (2002 - 2010)

1. **Postdoctoral Fellow**: Department of Microbiology and Immunology, Medical University of South Carolina, USA (2001 - 2002)
2. **Associate Professor**: Department of Zoology, Faculty of Science, Tanta University,

Egypt (2001 - 2005)

1. **Research Fellow**: Department of Immunology Kyushu University, Japan (1997 - 2000)
2. **Assistant Lecturer**: Department of Zoology: Faculty of Science, Tanta University,

Egypt (1995 - 1996)

1. **PhD Researcher**: Department of Immunology, Kyushu University, Japan (1992 - 1994)

**CURRENT AND PAST ADMINISTRATION POSITIONS**

* **Director,** Competitive Project Unit, June 2010-June 2013
* **Director**; Grants, Innovation & Technology Transfer Center, Tanta University, Egypt (July 2013 - Present).
* **Director**, Center of Excellence for Cancer and Stem cell Research; Tanta University, Egypt (July 2013 - Present).
* **Supervisor**, Vaccine Laboratory, Surgical Oncology, Surgery Department, Medical University of South Carolina, USA (2004 – 2010)

**RESEARCH INTERESTS**

* Understanding the cellular and molecular mechanisms governing the dysfunction of anti-cancer and anti-viral immune responses
* Developing effective anti-tumor immunotherapeutic regimen
* Modulation of immune cells using natural products

**RESEARCH SUPPORT (GRANTS)**

***Completed Grants***

1. ***Altering post vaccination T cell contraction***

**Source: R01/**National Cancer Institute (Grant #: R01 CA083672-04a1)

**Period:** 1/4/2004-04/30/2009

**Fund:** $250,000/year (5 years)

**Role:** Co-Investigator; Principle Investigator, David J Cole

1. ***Preclinical assessment of the novel peptide-based cancer vaccine F2 gel/CEA/IL-12***

**Source:** Department of Defense (DOD) (Grant#: GC-3609-04-43766CM)

**Period:** 11**/**01/2004-10/31/2006

**Fund:** $80,000/year (2 years)

**Role**: Principle Investigator

1. ***Immature myeloid immunosuppressor cells in breast cancer patients: Implications for anti-tumor vaccination***

**Source:** Hollings Cancer Center, Medical University of South Carolina

**Period:** 01/01/2005-12/13/2007

**Fund:** $55,000/year (1 year)

**Role**: Principle Investigator

1. ***Circulating myeloid suppressor cells in breast cancer patients: Implications for future vaccine development***

**Source**: Chain Reaction for a Cure a Breast Cancer

**Period**: 01/01/05-21/31/2006

**Fund:** $15,000 (1 year)

**Role**: Principle Investigator

1. ***Evaluation of F2 gel/IL-12-based vaccination on hepatic fibrosis and protection after Schistosoma mansoni infection***

**Source:** Marine Polymer Technologies Inc., Danvers, Massachusetts

**Period:** 06/01/2004-3/30/2007

**Fund:** 180,000 L.E. (30 months)

**Role**: Principle Investigator

1. ***In Vivo Effector T Cell Response to Peptide Vaccination***

**Source***:* National Cancer Institute (R01)

**Period:** 07/01/01-06/30/2004

**Fund:** $250,000 (3 years)

**Role**: Co-Investigator; Principle Investigator, Dr. David J Cole, MD

1. ***Characterization of p-GlcNAc as an immune adjuvant and a delivery system for cytokines***

**Source:** Marine Polymer Technology, Boston, USA

**Period**: 07/01/01-06/30/2004

**Fund:** $32,000 (30 months)

**Role**: Co-Investigator; Principle Investigator, Dr. William Gillanders, M.D.

1. ***New Technology for control of the intermediate host of schistosomiasis in Egypt, Laboratory and semi field application***

**Source**: Tanta University, Egypt

**Period**: 01/01/97-12/31/2003)

**Fund:** 100,000 L.E./year (3 years)

**Role**: Co-Investigator; Principle Investigator, Dr. Mohamed Mona, PhD

***Active Grants***

1. ***Establishing Grants, Innovation & Technology Transfer Center (GITTC) at Tanta University.***

**Source:** Academy of Scientific Research and Technology, Egypt

**Period:** 1/06/2013- 31/05/2015

**Fund:** 700,000 L.E. (about $100,000)

**Role:** Principal Investigator

1. ***Establishing Center of Excellence of Cancer Research (CECR) at Tanta University (Project ID#: 5245)***

**Source:** Science and Technology Development Fund (STDF), Egypt

**Period:** 1/04/2013- 31/03/2016

**Fund:** 9,650,000 L.E. (about $1.800,000)

**Role:** Principal Investigator

1. The use of artesunate-loaded nanoparticles tagged with transferrin as a novel targeting therapy of experimental colon cancer ***(Project ID#: ????)***

**Source:** Science and Technology Development Fund (STDF), Egypt

**Period:** 1/12/2013- 30/11/2015

**Fund:** 1000 ,000 L.E. (about $150,000)

**Role: Co-**Principal Investigator

1. **Responsible Conduct of Scientific Research**

**Source:**  National Academy of Sciences, USA

**Period:** 1/6/2013-31/12/2013

**Budget:** $1,500 (10,000 L.E.)

**Role:** Principal Investigator

1. ***Impact of novel artesunate-loaded nanoparticles tagged with transferrin in treatment of experimental colon cancer***

**Source:** Science and Technology Development Fund (STDF), Egypt

**Period:** 01/10/2013- 30/9/2015.

**Fund:** 1,000 ,000 L.E. (about $180,000)

**Role: C0-**Principal Investigator

1. ***Dysfunctional myeloid cells as a predictor of failure of chronic HCV patients to interferon therapy (Project ID#*** 1469***)***

**Source:** Science and Technology Development Fund (STDF), Egypt

**Period:** 31/08/2010- 30/10/2013.

**Fund:** 1,736,160 L.E. (about $300,000)

**Role:** Principal Investigator

1. ***Maximizing memory T cell responses by matured post chemotherapy dendritic cells***

**Source: R01**/National Cancer Institute (Grant #: RCA133503A)

**Period:** 4/1/2010- 3/31/2013

**Fund:** $250,000/year (3 years)

**Role**: ***Principle Investigator from March 2010-October-2010. Curent role: Consultant*.**

**PRIZES, HONORS and AWARDS**

1. **Prizes**

* ***State's Excellence Award in Basic Sciences (2009/2010):*** *A*cademy of Scientific Research and Technology, Egypt.
* ***State's Incentive (Encouraging) Award in Biology (2003/2004***): Academy of Scientific Research and Technology, Egypt.

1. ***Awards***

* ***T****he* ***Educational Institute on Responsible Research on Infectious Diseases: Ensuring Safe Science in the 21th Century*** sponsored and organized b U.S. National Academy of Sciences, Aqaba, Jordan, 8-13 September, 2012.
* ***Senior Research Fellowship Award to visit Medical University of South Carolina, USA for 6 months***, Ministry of Higher Education, Egypt (July 2012).
* ***Selective Poem award***: "Title: We All Shall Die", International Society of Poets, 2006.
* ***Selective Poem award***: "Painless Pain", International Society of Poets, 2006.
* ***Research Excellence Award***: Marine Polymer Technologies, Inc., 2006
* ***Research Fellow Scholarship***, Ministry of Higher Education, Japan (October 1997-March, 2001)

1. **Recognition**

* ***Distinguished Award,*** Association for American-Egyptian Scholars in North America during the Annual Meeting of the association from 27-28/12/2012, Ain Shams University, Cairo, Egypt.
* ***2011 CAS-TWAS Visiting Scholar Award:*** Third World Academy of Science (TWAS), 2010. Three-month award to visit Chinese Academy of Science.
* ***Tanta University (Egypt) Shield***: Tanta University, as recognition for the scientific achievement, November, 2010.
* ***The Conference Shield***: the 6th International Conference on Biological Sciences, Faculty of Science, Tanta University, Egypt, November 2010.
* ***Tanta University (Egypt) Shield***: Tanta University as recognition for the scientific achievement, November, 2004.
* ***Certificate of Merit***: the First Conference of Applied Prophetic Medicine organized by Abha Private Hospital, Saudi Arabia in the period from 19 to 21 February 2008.
* ***Certificate of Merit***: National Science Club Committee, during the first meeting of the Science Clubs competition for the Universities of Egypt, which was held at Cairo University 21/11/1996.

**TEACHING EXPERIENCE**

1. **Medical University of South Carolina, USA**

***Tumor Immunology:*** Postgraduate Students, Development of Molecular Cancer Therapies (Course ID: MBIM 716); Basic Immunology (Course ID: MBIM 775\*01) (2005-2010)

1. **Kafr Elsheikh University, Egypt**

***Immunology and Hormones:*** Postgraduate students, Zoology Department, Faculty of Science (2012/2013).

1. **Damanhur University, Egypt**

***Stem Cell Research:*** Postgraduate students, Zoology Department, Faculty of Science (2012/2013).

***Immunology:*** Postgraduate students, Zoology Department, Faculty of Science (2012/2013).

1. **Damietta University, Egypt**

***Immunology and Enzymes:*** Postgraduate students, Zoology Department, Faculty of Science (2012/2013).

1. **Tanta University, Egypt**

***Cell Biology and genetics:*** 2nd year Undergraduate Students, Biochemistry and Biophysics Department, Faculty of Science (2012/2013).

***Immunology:*** Postgraduate Students, Biochemistry and Zoology Department, Faculty of Science (2012/2013).

***Cancer Biology:*** Undergraduate Biochemistry students (4th grade), Chemistry Department, Faculty of Science (2010/2011)

***Immunology:*** Undergraduate Biochemistry students (4th grade), Chemistry Department, Faculty of Science (2010/2011)

***Genetics and Molecular Biology:*** Undergraduate Biology students (2nd Grade, Division of Biology, Faculty of Science (1996/1997; 2010/2011 and 2011/2012).

***Experimental Biology (Immunology):*** Postgraduate students, Zoology Department, Faculty of Science 1996/1997; 2010/2011; 2011/2012.

**EXTERNAL GRADUATE THESIS EVALUATION COMMITTEE**

**MASTER:** 6 Theses

**DOCTORATE:** 5 Theses

**ARBITRATION COMMITTEES:** 14 Associate and Full Professorship cases from Egypt, Yemen, Iraq, and Lebanon

**GRADUATE THESIS COMMITTEE MEMBER**

**Master theses (M.Sc.):** 23 Theses

**Theses (Ph.D.):** 12 Theses

**LABORATORY SUPERVISION DUTIES**

* + Research Specialists at Tanta University, Egypt (3 fellows)
  + Research Specialists at Medical University of South Carolina, Charleston, USA (9 fellows)
  + Visiting Fellows at Medical University of South Carolina, USA (3 fellows)
  + Graduate Students at Medical University of South Carolina, USA (5 fellows)
  + Undergraduate Students*, Tanta University* (8 fellows)

**National/International COMMITTEES**

***Extramural Committees***

* ***Member and Secretary,*** The University Steering Committee for over viewing the funded projects at Tanta University funded by National and International sources. June 2013-now
* ***Coordinator, Establishing Biobank at Center of Development of Delta Region, Tanta.***  This project is initiated by the Academy of Scientific Research and Technology (ASRT), Cairo, Egypt with scientific collaboration with Tanta University, Egypt. October 2012-now.
* ***Coordinator, Faculty of Science Ethical Committee,*** Faculty of Science, Tanta University, Egypt, December 2012.
* ***Member, Center of Environmental Outreach and Sustainable Development***, Tanta University, December 2012.
* ***Member, College Board, Faculty of Science****, Tanta University*, October 2012-September 2013.
* ***Member, Institutional Animal Care Ethical Committee,*** *Zoology Department, Faculty of Science, Cairo University, Egypt*
* ***Member, Egyptian Universities Promotion Committee (EUPC):*** *Zoology and Entomology Committee, 2012-2015 cycle.*
* ***Member, Tanta University Committee for Award and Prize,*** *Tanta University, Egypt.*
* ***Member of the Board of Directors,*** Community Service and Environment Development, Faculty of Medicine, Tanta University, Egypt, 2010/2012.
* ***Member,* Community Service *and Environment Development****, Faculty of Science, Tanta University, Egypt; 2010/2012*
* ***Executive member, Board of Director, Condolence Society of Hematological Diseases for Patients and Family***, Egypt.
* ***Executive member, Middle-Eastern Association for Cancer Research* (MEACR), Canada**
* ***Senior Supervisor,*** Animal House Supervision Committee, Zoology Department,Faculty of Science, Tanta University, Egypt, October, 2011.
* ***Member, Advisory Board****; the* National Authority for Quality Assurance and Accreditation of Education **"**NAQAAE**".**
* ***Member, Crisis and Emergency Committee,*** Faculty of Science, Tanta University, Egypt, January-February, 2011.
* ***The Principal Coordinator,*** the Collaborative Scientific Research Committee of Tanta University and Mubarak City for Scientific Research and Technology Applications ***(MuCSAT).*** Tanta University, Egypt, 2010.
* ***Member, Postgraduate Committee for Postgraduate Courses, Faculty of Science,*** Tanta University, Egypt; 2010/2012.
* ***Member, Postgraduate Research Committee of Zoology Department,*** Faculty of Science, Tanta University, Egypt; 2010/2012.
* ***Advisory Committee For Flow Cytometry Facility***: Hollings Cancer Center, Medical

University of South Carolina, Charleston, SC, USA (2007 - Present)

* ***Moderator****,* the weekly Journal Club at Hollings Cancer Center (2003-2009): The main goal of this club is to present of papers published in state-of-art journals in the field of immunology. Members of this club included postgraduate students, postdoctoral fellow and faculty at the Medical University of South Carolina, USA.
* ***Member***, the committee to assess the molluscicidal of plant origin (Ammi Damsisp and Gheit soap), the Institute of Theodore Bilharz, Giza, Egypt on May 27, 1997.
* ***Member***, committee responsible for the computers, Department of Zoology, Faculty of Science, Tanta University (1996/1997).
* ***Member***, the preparatory committee formed by the Faculty of Science, Tanta University, to organize the graduation day for the year 1996/1997.
* ***International Program Committee*** (Nanotechnology '09), Cambridge, UK, 21- 23/2, 2009

***Coordinator, How to write a TEMPUS project:*** A workshop organized by Competitive Project Unity, Tanta University on December 10, 2012, Faculty of Medicine, Tanta University, Egypt.

***Coordinator, Writing a Scientific Proposal for PostDoc,*** A workshop organized by Competitive Project Unity in collaboration with DAAD, Cairo on December 16, 2012, at Development Project Unity, Tanta University, Egypt.

***Coordinator, How to write a competitive project:*** A workshop organized by Competitive Project Unity, Tanta University on September 12, 2012, Faculty of Agriculture, Tanta University, Egypt.

**Conferences committees**

1. ***Session Chair,*** *2013 Montreal International Forum on Immunology, Montreal, Canada, 19-20 October, 2013.*
2. ***Coordinator, Biotechnology Session, The 28th Annual congress of Tanta Faculty of Medicine: Quality and Medicine***, Tanta University, Egypt, 4-8 March, 2013.
3. ***Coordinator: The 3rd conference on Enhancing Scientific Research****, Tanta University, Egypt, from 18-19 November 2012 (*[*http://www.tanta.edu.eg/ar/Conf/Index.html*](http://www.tanta.edu.eg/ar/Conf/Index.html))*.*
4. ***Co-Chair,*** *"Liver viruses and stem cells*" session, The 8th Conference on Liver and Environment "Risks and solution": Towards a new strategy for control of liver diseases, Faculty of Medicine, Tanta University, 7-8 November, 2012.
5. ***Co-Chair, Hematology and Oncology Session***, The 27th Annual Conference of Faculty of Medicine, Tanta University, 17-21 April, 2012.
6. ***Session Chair (*Immunotherapy**): TM's 1st World Immunology Online Conference, New York Time, March 16, 2012
7. ***Chairman***, ***the First Conference of the Middle-Eastern Association for Cancer Research (MEACR)***, Tanta University Convention Center, 27-29/12/2011.
8. ***International Coordinator****;* The 3rd International Conference on Environmental Sciences organized by Tanta University, Egypt, November 2011.
9. ***Coordinator, International Communication***, The 7th International Conference on Biological Sciences, organized by Botany and Zoology Departments, Faculty of Science, Tanta University, Egypt: 5-6, 12, 2012.
10. ***Co-Chair, "Immunology" session***, The 7th International Conference on Biological Sciences, December 5-6 2012.
11. ***International Coordinator***, ***Co-Chair, Plenary Session and The Junior Scientific Session***: The 6th International Conference on Biological Sciences, organized by Botany and Zoology Departments, Faculty of Science, Tanta University, Egypt, November 2010.
12. ***Scientific Committee***: The 6th International Conference on Biological Sciences, organized BY Botany and Zoology Departments, Faculty of Science, Tanta University, Egypt***.***
13. ***Scientific Committee***: The 5th International Conference on Biological Sciences, organized BY Botany and Zoology Departments, Faculty of Science, Tanta University, Egypt
14. ***Scientific Committee,*** *The 2nd Annual Meeting of Middle-Eastern Association for Cancer Research (MEACR 2012)*, Tunisia, 27-29, 12, 2011.
15. ***Coordinator and Co-Chair***, Stem Cell Therapy: Egyptian Experiences: Faculty of Medicine, Tanta University, Egypt, 17/10/2011. Session Chair.
16. ***Coordinator***, Development of Self and Exploring the Skills, Organized by Tanta Science Society, Faculty of Science, Tanta University, Egypt, October 18, 2011.

**GRANT REVIEWS DUTIES (AD HOC REVIEWER)**

* *Ad Hoc* Science & Technology development Fund (STDF); Cairo, Egypt since September 2013.
* *Ad Hoc* Scientific Reviewer: Misr Elkher (MEK); Cairo, Egypt since July 2013.
* Academy of Scientific Research and Technology (ASRT); Cairo, Egypt since December 2010.
* King Abdel Aziz City for Science and Technology (KACST), King Saudi Arabia since January 2011.
* Deanship of Scientific Research, King Saud University, King Saudi Arabia since February 2011.
* 2009 Breast Cancer Research Program - Idea and Postdoctoral-Endocrinology/Immunology (CDMRP BCRP IPD-END/IMM Panel), Department of Defense, Washington DC, January 2010.
* Special Emphasis Panel (ZRG1 BSTM 58, 7/20/2009-7/21/2009), National Institute of Health, Washington DC
* *Broad Medical Research Program, USA* (August 2004)
* *Swiss National Science Foundation, (Berne, Switzerland)*
* Egyptian Universities Promotion Committee (EUPC) (Basic Sciences; Zoology Committee); the 10 cycle from 2008-2011.

**JOURNAL REVIEWS (AD HOC REVIEWER)**

1. *Animal Biology*
2. *African Journal of Biotechnology*
3. *Agriculture Research*
4. Archives of Medical Research
5. *Arthritis and Rheumatism*
6. *BioDrugs*
7. *Biologics: Targets & Therapy*
8. *Cancer Immunology and Immunotherapy*
9. *Cancer Research*
10. *Cancer: Targets and Therapy*
11. *Cellular Immunology*
12. *CURRENT CANCER DRUG TARGETS*
13. *Current Drug Target*
14. *Cytokine*
15. *Cytotechnology*
16. *Egyptian Journal of Parasitology*
17. *Endocrine Metabolic Immune Disorders- Drug Targets*
18. *European Journal of Gastroenterology & Hepatology*
19. *Evidence Based Complementary & Alternative Medicine*
20. *Experimental Lung Research*
21. *Experimental Parasitology*
22. *Expert Review of Vaccines*
23. *Finding in Exp. and Clinical Pharmacology*
24. Fundamental & Clinical Pharmacology
25. Future Drugs Ltd
26. *Hematology Research and Reviews*
27. *Human Immunology*
28. Ibnosina Journal of Medicine and Biomedical Sciences
29. *Immunology and* Cell *Biology*
30. *Immunology Letter*
31. International J Medicine & Medical Sciences
32. International J Pharmacy & Pharmacology
33. *International Immunopharmacology*
34. ISRN Immunology
35. *J Advanced Research*
36. *J Basic and Applied Zoology*
37. *J Biological Sciences*
38. *J Biomaterials Science: Polymer Edition*
39. *J Clinical Immunology and Immunopathology Research*
40. *J Cellular and Molecular Medicine*
41. *J Environmental Chemistry and Ecotoxicology*
42. *J Genetic Engineering and Biotechnology*
43. *J Immunology and Cell Biology*
44. *J Infection in Developing Countries*
45. *J Interferon and Cytokine Research*
46. *J Medical Laboratory and Diagnosis*
47. *J Medicine and Medical Sciences*
48. *J Neuroimmunology*
49. *J Parasitology Research*
50. *J Pharmacy and Pharmacology*
51. *J Pharmacy and Bioallied Sciences*
52. J Zhejiang University-SCIENCE B
53. *Medical Principles and Practice*
54. *Medical Science Monitor*
55. *Methods and Findings in Experimental & Clinical Pharmacology*
56. *OncoTargets and Therapy*
57. *Oral Diseases*
58. *Pharmaceutical Biology*
59. Planta Medica
60. Recent Patents on Inflammation & Allergy Drug Discovery
61. Saudi Medical Journal
62. The Egyptian J of Experimental Biology
63. The Egyptian J of medical Sciences
64. The Open Vaccine Journal
65. Toxicology
66. Turkish Journal of Veterinary & Animal Sciences
67. Vaccine
68. Universal Journal of Medicine & Dentistry

**Editorial board review duties**

1. American Journal of Biomedical Research
2. Cancer Research Journal
3. Bioscience
4. Journal of Basic and Applied Zoology, Chief-Editor of Immunology.
5. Egyptian J Parasitology.
6. *Egyptian Journal of Experimental Zoology, Egypt*
7. American Journal of Immunology (Science Publication); Regional Editor
8. The Scientific World JOURNAL (Immunology and Inflammation)
9. The Open Cancer Immunology Journal
10. Hematology Research and Reviews; Dove Medical Press; Honorary Editor
11. The Clinical Cancer investigation Journal
12. Journal of Vaccine and Vaccination
13. ISRN Immunology
14. Journal of Vaccine and Vaccination

**INVITED TALKS**

1. ***Myeloid dells as a double-edge sword in cancer immunotherapy:*** Saint Justin Research Center Hospital, University of Montreal, Canada, 22/10/2013
2. ***Writing a fundable research proposal. F***aculty of Science, Assuit University, Egypt, May 1-2, 2013.
3. ***Concept of Grant writing,*** Tanta University Staff Club, Tanta University, Egypt, May 22 and 25, 2013.
4. ***Concept of Grant writing: STDF as a model,*** Faculty of Science, Suez University, Egypt, May 22 and 25, 2013.
5. ***The use of Endnote in citation and bibliography.*** ICTP center, **Tanta University Project Management Unit,** Tanta University, March 23, 27, and 30, 2013.
6. ***National and International funding sources for competitive research projects.*** *Faculty of Nursing, Tanta University, Egypt, March 24, 2013.*
7. ***How to turn your research idea into a fundable project.*** Faculty of Science, Sue University, Egypt, April 29, 2013.
8. ***The Use of Animals in Research,*** a workshop organized by Egyptian-German Society of Zoology, held at Faculty of Science, Cairo University, Cairo, Egypt, December 30, 2012.
9. **Role of immune regulator cells in development of cancer:** The 5th Annual Histopathology Course. International Medical Center (IMC), February 25th to March 3th, 2013.
10. **Dendritic cells in renal disease:** The 5th Annual scientific Conference of IMC Updates in nephrology and renal transplant. February 25th to March 3th, 2013.
11. ***International Publications and Intellectual property Right*** toFaculty Members at Faculty Agriculture, Kafr Elsheikh University, December 19, 2012.
12. ***Writing Competitive Research Project to*** Faculty Members at Faculty and Leadership Development Center (FLDP program), Project Management Unit, Kafr Elsheikh University, December 4, 2012.
13. ***A Novel escape mechanism of cancer from immunotherapy***, A plenary lecture presented at The 7th International Conference on Biology, Tanta University, 5-6 December, 2012.
14. ***Cellular and Molecular Tumor Markers***: The 1st Scientific Conference of Laboratory Diagnosis, 2 November 2012.
15. ***Immunotherapy of HCC:* The 8th Conference on Liver and Environment "Risks and solution": Towards a new strategy for control of liver diseases**, Faculty of Medicine, Tanta University, 7-8 November, 2012.
16. ***Novel Immunotherapeutic Strategies to Cure Cancer*,** Zewail City of Science and Technology, September 3, 2012
17. ***Stem cell-derived myeloid cells and the dysfunction in their maturation***. A plenary lecturer at the Medical tests workshop, Faculty of Science, Alexandria University, Egypt, July 18, 2012.
18. ***Anti-cancer chemo-immunotherapy: Learned preclinical lessons for potential clinical application.*** *Laser Institute, Cairo University, Egypt. 14/6/2012.*
19. ***How to turn your research idea into a fundable project.*** Faculty of Science, Cairo University, Egypt, May 27 and 4 June, 2012. A workshop organized by Egyptian-German Society of Zoology.
20. ***How does chemotherapy benefit cancer immunotherapy?*** TM's 1st World Immunology Online Conference, New York Time, March 16, 2012.
21. ***Egypt: The beating heart of the Middle East***. Key Lab. Infection and Immunity, Center of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, February 24, 2012.
22. ***Altering Myeloid cells by Chemotherapy: Implications for Cancer Immunotherapy***. Department of Biochemistry and Molecular Cell Biology, Institute of Medical Science, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China, February 21, 2012.
23. ***Potential strategies to enhance application of anti-cancer adoptive T cell immunotherapy***. Biotherapy Center of the First Affiliated Hospital & the Department of Bioengineering, Zhengzhou University, China, February 13, 2012.
24. ***Efficacy of Combinatorial anti-cancer chemotherapy and immunotherapy: A central role of dendritic cells***. Key Lab. Infection and Immunity, Center of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, February 9th, 2012.
25. ***Myeloid-derived suppressor cells: A limited factor for anti-tumor immunity***. Key Lab. Infection and Immunity, Center of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, February 16th, 2012.
26. ***Rebounding of Dendritic Cells Post Chemotherapy: Implication for cancer immunotherapy.*** *Vaccines and Vaccination 2011, Philadelphia, USA, 22-24 November, 2011.*
27. ***Optimizing Higher Education by Merging Teaching and Research skills***. The 1st International conference on Education Development organized by The 5th Meeting of Egyptian Association Abroad for Enhancement and Development of Education in Egypt (October 29-31, 2011). ***Cairo University, October 31, 2011.***
28. ***How Does Chemotherapy Enhance Adoptive Anti-Tumor T Cell Therapy***? Department of Microbiology and Immunology, University of Miami, May 26, 2011.
29. ***Laboratory Notebook Policy***: Center for Academic Development, Tanta University, Egypt, 15/3/2011.
30. ***Tools for Project Management***: Center for Academic Development, Tanta University, Egypt, 23/3/2011.
31. ***Self Experience in The Use of Adoptive T Cell Transfer in Anti-cancer Therapy***: The Annual Meeting of German-Egyptian Society of Zoology, *B*ani Sweif University, Egypt, February, 2011.
32. ***Competitive Research Status at Tanta University***; Faculty of Medicine, Tanta University, Egypt, December, 2010.
33. ***The concept of Grant Writing: STDF as A Model***; Faculty of Pharmacy, Tanta University, Egypt, December, 2010.
34. ***The concept of Grant Writing: STDF as a model grant***; Faculty of Dentistry, Tanta University, Egypt, September 22, 2010.
35. ***How to write a competitive research proposal***: Mubarak City for Scientific Research and Technology and Applications, Alexandria, Egypt, November, 2010.
36. ***Writing a competitive research proposal***: Faculty of Science, Tanta University, Egypt, May, 2010.
37. ***How to write a competitive research proposal***: Faculty of Science, Tanta University, Egypt, May, 2010.
38. ***How to write a competitive research proposal***: Faculty of Science, Alexandria University Damanhour Branch), Egypt, 28 June, 2010.
39. ***How to write a competitive research proposal: A focus on Science and Development Fund (STDF)***. Faculty of Science, Banha University, Banha city, Egypt, 27 June, 2010.
40. ***Immunosuppressive myeloid cells and anti-tumor immunity***: Mubarak City for Scientific Research and Technology and Applications, Alexandria, Egypt, June, 2010.
41. ***The potential application of the immunomodulatory adjuvant poly(I:C) in anti-tumor immunity***: Mubarak City for Scientific Research and Technology and Applications, Alexandria, Egypt, June, 2010.
42. ***Application of the toll-like receptor 3 agonist poly(I:C) as an adjuvant for cancer immunotherapy. Georgia Institute of Technology***. School of Chemistry and Biochemistry. Atlanta, Georgia, March 8, 2010
43. ***Fostering Research in the Research Institutes in Egypt***. Invitation through the TOKTEN Project of the Egyptian Academy of Scientific Research and Technology (ASRT) to participate in The 2nd International Conference for Enhancing Scientific Research held at Tanta University, Egypt, March 4 - 5, 2009.
44. ***Vivarium and Institutional Regulation: A Must For A Successful Research***. Tanta University, Tanta, Egypt. November 25, 2008.
45. ***Chemotherapy: Friend or foe for cancer Immunotherapy***. Tanta University, Tanta, Egypt. November 5, 2008.
46. ***Chemotherapy: Friend or foe for cancer Immunotherapy***: Mubarak City for Science and Technology, Alexandria, Egypt. November 24, 2008.
47. ***Immunomodulatory and immunotherapeutic potentials of Nigella sativa, the black seed.*** The 1st International Conference on Prophetic Medicine, Abha Private Hospital, Abha, Saudi Arabia, King Saudi Arabia, February, 2008.
48. ***Lymphodepletion: A bad for good immunotherapy:*** Internal Speaker, Cancer Immunology and Immunotherapy Lecture Series, Hollings Cancer Center, Medical University of South Carolina, Charleston, USA. February 2008.
49. ***Development of Molecular Cancer Therapies: From Bench to Bedside of Cancer Vaccines***. Department of Microbiology and Immunology, Medical University of South Carolina, USA.
50. ***Optimizing Cancer Immunotherapy By Creating Beneficial Host Microenvironments***: Department of Surgery, Medical University of South Carolina, USA; June 11, 2007.
51. ***Novel Adjuvant Approaches for Optimization of Peptide-based Cancer Vaccines***: College of Medicine and Health Sciences, United Arab Emirates University, United Arab Emirates, Al-Ain, United Arab Emirates, 30 May, 2004
52. ***Optimization of T cell responses to vaccination: Applications for cancer immunotherapy***. Permanent Scientific Committee for Professorship Promotion, Ministry of Higher Education, Ain Shams University, Egypt, November 15, 2006**.**
53. ***Influence of Female Sex Hormones on Immune Responses***. Center for Biomedical Physics, Temple University School of Medicine, Philadelphia, Pennsylvania, USA. 24 November, 2000.

**Sabbatical Leave**

1. **USA:** Visiting Professor, Department of Microbiology and Immunology, Medical University of South Carolina, USA from 29/1/2013 to 20/2/2013
2. **USA:** Visiting Professor, Department of Microbiology and Immunology, Medical University of South Carolina, USA from 29/1/2013 to 20/2/2013
3. **China:** Key Lab. Infection and Immunity, Center of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, February 24, 2012. This scientific mission was a **Visiting Professorship** supported mutually by the Third World Academy of Sciences (TWAS) and the Chinese Academy of Sciences (CAS).
4. **USA:** Surgery Department and Hollings Cancer Center, Medical University of South Carolina, USA from 6/2001 to 6/2002. This scientific mission was a **Post-Doctoral Fellowship** supported by R01 grant from National Cancer Institute, National Health Institute, USA.
5. **USA:** Surgery Department and Hollings Cancer Center, Medical University of South Carolina, USA from 6/2002 to 6/2010. This is an **Assistant Professorship** supported by R01 grant from National Cancer Institute, National Health Institute, USA.
6. **Japan**: Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Japan. **PhD Researcher** from 10/1992 to 12/1994. This scientific mission was supported by a 27-month scholarship from the Ministry of Higher Education and Scientific Research, Egypt.
7. **Japan**: Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Japan from 10/1997 to 1/1998. This scientific mission was a **Research Non-Degree Student (Monbukagakusho Scholarship)** supported by a 15-month scholarship from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
8. **Japan**: Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Japan from 1/1999 to 3/2001. This scientific mission was a **Research Non-Degree Student (Monbukagakusho Scholarship)** supported by a 3-year scholarship from the Ministry of Education, Culture, Sports, Science and Technology, Japan. I completed 2 years only and moved to USA.
9. **Italy:** Tumori Instituti Pascali. This scientific mission was a **Junior Researcher Travel Award** from Tumori Instituti Pascali to attend HLA and Tumors workshop, Napoli, Italy from December 2-6, 1996.
10. **Italy:** Tumori Instituti Pascali. This scientific mission was a **Junior Researcher Travel Award** from Tumori Instituti Pascali to attend Immunosuppressive Drugs & the Immune System, Napoli, Italy from 2-11 Nov., 1994.

**BIBLIOGRPAHY:**

**Original Articles**

***\*, Corresponding authors***

1. Mo'ez Al-Islam E Faris, Safia Kacimi, Ref’at A Al-Kurd, **Mohamed L. Salem**, Yasser K Bustanji, Mohammad Mohammad: Intermittent Fasting during Ramadan Attenuates Proinflammatory Cytokines and Immune Cells in Healthy Subjects. ***Nutrition Research, 2012 Dec;32(12):947-55.***
2. **Mohamed L Salem**, Abdel-Aziz A Zidan, Mohamed Abou Senna, Abdel Raouf Abou Al-Azm, Hasan Albatei, Maha Aldemelaawy, Mohamed Attia. Frequencies of circulating myeloid derived suppressor cells and dendritic cells in Egyptian patients with chronic Hepatitis C Virus infection undergoing treatment with IFN-a-based therapy. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P248 (http://www.immunotherapyofcancer.org/content/1/S1/P248). ***From Society for Immunotherapy of Cancer 28th Annual Meeting National Harbor, MD, USA. 8-10 November 2013.***
3. Mark P Rubinstein, **Mohamed L Salem**, Andrew L Doedens, Caitlin J Moore, Cody Chiuzan, Guillermo L Rivell, David J Cole and Ananda W Goldrath. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. ***J Hematology & Oncology 2013, 6:75.***
4. Abdel Raouf Abou El-Azm, Hassan El-Bate, Lobna Abou-Ali, Nagwa Mansour, Hussin Ghoraba and\***Mohamed L. Salem**. Correlation of the viral load with bone marrow changes and hematological abnormalities in pale patients with chronic hepatitis C virus*.* ***Archive Virology,*** 2012 Aug;157(8):1579-86***.***
5. \***Mohamed L. Salem**, Amir A. Al-Khami, Sabry A. El-Nagaar, Abdel-Aziz A. Zidan, Ismail M. Al-Sharkawi, C. Marcela Díaz-Montero, David J. Cole: Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. ***Cellular Immunology. 2012, 376(1-2): 67-74***
6. Mark P. Rubinstein, Colleen Cloud, Tracy Vandenberg, Caitlin J. Moore, Kristina M. Schwartz, C. Bryce Johnson, David H. Craig, **Mohamed L. Salem**, Chrystal M. Paulos, David J. Cole: Ex vivo IL-12-priming during CD8+ T cell activation dramatically improves adoptive T cell transfer anti-tumor efficacy in a lymphodepleted host. ***J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. Epub 2012 Feb 22.***
7. Faris Q Alenzi, Fawwaz A. Alenazi, Yehia Al-Kaabi, and \***Mohamed L Salem**: The use of growth factors to modulate the activities of antigen-specific CD8+ T cells in vitro. ***J Med Life. 2011 Nov 14;4(4):399-406. Epub 2011 Nov 24.***
8. Faris QB Alenzi, Mahmoud Lotfy, Wasam Nasif, Mohamed El-Shahat, Mohamed Alenazi, Fawwaz A Alenazi, Waleed G Tamimi, Hasan Abusini, **Mohamed L Salem**: Biomedical research in the middle eastern countries: Update and insight using scimago Journal Rank Indicator. ***J Ayub Med Coll Abbottabad 2010;22(3):*** 100-5***.***
9. Marcela Diaz,Osama Naga, Sherif Zidan, **Mohamed L. Salem**, David Cole, Alberto J Montero. [Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.](http://www.ncbi.nlm.nih.gov/pubmed/21915391) ***Am J Cancer Res. 2011 August 30; 1(7): 882–896.***
10. **\*Mohamed L Salem, Faris Q. Alenzi**. Thymoquinone, the active ingredient of *Nigella sativa* seeds, enhanced survival and activities of the antigen-specific CD8 T cells in vitro. ***British J Biomedical Sciences,*** ***2011;68(3):131-137.***
11. Faris Q. Alenzi, **Mohamed L. Salem**, Waleed G. Tamimi, Mahmoud Lotfy, Ali A. Aljabri, Saad S. Al-ghamdi*,* Laila Damanhouri, Talat Bukhari and Richard K.H.Wyse. NKH477 inhibits proliferatiofn and induces apoptosis in a panel of cancer cell lines. ***J. Postgraduate Medical Institute (JPMI), 2010: 24(3):182-187.***
12. Faris Alenzi, Yousry E. Al-Bolkiny, **Mohamed L. Salem**: Protective effects of *Nigella sativa* oil and thymoquinone against toxicity induced by the anti-cancer drug. ***Br J Biomed. Sci. 2010;67(1):20-8.***
13. **\*Mohamed L. Salem**, Wael Attia, Yousry E. Al-Bolkiny, Ismail M. Al-Sharkawi, Marina Demcheva, and John Vournakis. Using poly-N-acetyl glucosamine gel matrix to deliver IL-12 with anti-schistosomasis vaccination. ***J Infect Dev Ctries. 2010 Jun 3;4(5):318-328.***
14. Faris Q. Alenzi, Badi Q. Alenazi, Shamweel Y. Ahmad, Maher M. Al-Enazi, Esam H. Matter, **Mohamed L. Salem**, Ali A. Al-Jabri, Mahmoud Lotfy, Mohammad S. Bamaga,and Richard N. Wyse. The role of caspase activation and mitochondrial depolarisation in cultured human apoptotic eosinophils. ***Saudi Journal of Biological Sciences, 2010, 17:(1):*** 29-36.
15. **\*Mohamed L. Salem**, Amir A. AL-Khami, Sabry A. EL-Naggar, C. Marcela Díaz-Montero, Yian Chen, and David J. Cole: Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a FLT3L-dependent expansion of dendritic cells*.* ***J Immunology 184: 1737-1747, 2010****.*
16. **\*Mohamed L. Salem**, Sabry A. El-Naggar, David J. Cole: Cyclophosphamide induces bone marrow to generate high numbers of functional dendritic cells in vitro with adjuvant effects to T cell responses in vivo. ***Cell Immunology 2010;261(2):134-143.***
17. **\*Mohamed L. Salem**, C. Marcela Díaz-Montero, Amir A. AL-Khami, Sabry A. EL Naggar, Osama Naga, Alberto J. Montero, Ahmed Khafagy, and David J. Cole Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination anti-tumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). ***J Immunology, 2009(182)15:* 2030-2040***.*
18. **\*Mohamed L. Salem**, C. Marcela Diaz-Montero, Sabry A. EL-Naggar, Omar Moussa, Yian Chen, and David J. Cole: The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice. ***Vaccine, 2009, 27: 549-557.***
19. Mark P Rubinstein, **Mohamed L. Salem**, Andre N Kadima, Christophe L Nguyen, William E Gillanders, David J Cole. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. ***Cancer Gene Therapy, 2009 Feb;16(2):171-183.***
20. Alberto J Montero, **Mohamed L. Salem**, Elizabeth Garrett-Mayer David Cole, Marcela Diaz. Increased Levels of Circulating Myeloid-Derived Suppressor Cells in Solid Tumor Patients Correlate With Advanced Clinical Cancer Stage, Increased Tumor Burden, and Cyclophosphamide Containing Chemotherapy. ***Cancer Immunology and Immunotherapy.* 2009 Jan;58(1):49-59.**
21. Wael Y. Attia, Randa E. EL-Naggar, and **Mohamed L. Salem**. Quantitative and qualititative effects of eicosapentaenoic acid-28 (EPA-28) treatment on different immune cells of mice. ***Egypt. J. Exp. Biology. (Zool), 4:37-46, 2008.***
22. C. Marcela Díaz-Montero, Sabry El Naggar, Randa El Naggar, Amir Al Khami, Alberto J Montero., David J Cole., and **\*Mohamed L Salem**. Priming of naive cells in the presence of CD62Lhi IL-12 selectively enhances the survival of CD8+ CD62L cells and results in superior anti-tumor activity. ***Cancer Immunology & Immunotherapy, 2008 Apr;57(4):563-72.***
23. **\*Mohamed L. Salem**, Andre Kadima, Sabry EL-Naggar, and William E. Gillanders, David J. Cole. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. ***J Immunotherapy 2007 Jan;30(1):40-53.* (Corresponding Author)**
24. **\*Mohamed L. Salem**, Provision of cytokines and cytokine-inducing adjuvants along with peptide-based vaccination accentuated intrahepatic retention of antigen-activated CD8+ T cells: opposing roles for natural killer and Kupffer cells. ***Egyptian J. Experimental Biology. 2006, 2:33 - 47.***
25. **\*Mohamed L. Salem**, Andre Kadima, Sabry EL-Naggar, William E. Gillanders, and David J. Cole. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid (poly I:C) on antigen-specific CD8 T cell responses are partially dependent on NK cells and macrophages with the induction of a beneficial cytokine milieu. ***Vaccine. 2006 12(24):5119- 5132.***
26. **\*Mohamed L. Salem**, Mohsen Zommara and K. Imaizumi. Dietary supplementation of tiger nut (*Cyperus esculentus* L) attenuates inflammatory cell responses in apolipoprotein E knockout mouse. ***Amer Journal of Immunology 1 (1): 60-67, 2005.***
27. Narender Nath, Shalinendra Giri, Ratna. Prasad, **Mohamed L. Salem**, Avtar K. Singh, and Inderjit Singh. 5-aminoimidazole-4-carboxymide ribonucleoside: a novel Immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE). ***JImmunology 2005 Jul 1;175(1):566-74.***
28. **Mohamed L. Salem**, Andre N Kadima, David J Cole, William E Gillanders. Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling: Evidence of Enhanced Primary and Memory CD8 T-Cell Responses and Antitumor Immunity. ***J Immunotherapy 2005 May-Jun;28(3):220-8.***
29. **\*Mohamed L. Salem**, Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines. ***Int. Immunopharmacology. 2005, Vol 5/6 pp 947-960.***
30. Osta WA, Chen Y, Mikhitarian K, Mitas M, **Mohamed L. Salem**, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. ***Cancer Res. 2004 Aug 15;64(16):5818-24.***
31. **Mohamed L. Salem**, Andre N Kadima, Yuehua Zhou, Christophe L Nguyen, Mark P Rubinstein, Marina Demcheva, John N Vournakis, David J Cole, William E Gillander Paracrine release of interleukin-12 stimulates interferon-gamma production an dramatically enhances antigen-specific T-cell response after vaccination with a novel peptide-based cancer vaccine. ***J Immunology 2004 May 1;172(9):5159-67.***
32. Christophe L Nguyen, **Mohamed L. Salem**, Mark P Rubinstein, Marina Demcheva, John N Vournakis, David J Cole, William E Gillanders. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). ***Vaccine 21:2318-2328, 2003***
33. Mark P Rubinstein, Andre N Kadima, **Mohamed L. Salem**, Christophe L Nguyen, William E Gillanders, David J Cole. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. ***J Immunology 170:1209-17, 2003***
34. Mark P Rubinstein, Andre N Kadima, **Mohamed L. Salem**, Christophe L Nguyen, William E Gillanders, David J Cole. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. ***J Immunology 169:4928-35, 2002.***
35. **\*Mohamed L. Salem**, K. Kishihara and K. Nomoto. N-3 Polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function of T cells and macrophages. ***Anticancer Research 20:3195-3204, 2000.***
36. **\*Mohamed L. Salem** and Hossain M. Shorab. In vivo acute depletion of CD8+ T cells upregulates the anti-viral activity of NK cells against murine cytomegalovirus. ***Int. J. Immunopharmacology. 22:707-718, 2000.***
37. **\*Mohamed L. Salem** and Hossain M. Shorab. Protective effect of the black seed oil from Nigella sativa against murine cytomegalovirus infection. *Int. J. Immunopharmacology. 22:729-40, 2000.*
38. **\*Mohamed L. Salem**, Matsuzaki G., Kishihara K., Madkour G. and Nomoto K. β-estradiol suppresses the T cell-mediated delayed-type hypersensitivity through suppression of antigen presenting cell function and Th1 induction***. International Archives of Allergy and Immunology 121:161-169, 2000.***
39. **\*Mohamed L. Salem**, Hossain SM, and Nomoto K. Mediation of the immunomodulatory effects of β-estradiol on inflammatory responses by inhibition of recruitment and activation of the inflammatory cells, and their gene expression of TNF-alpha and IFN-gamma ***International Archives of Allergy and Immunology 121:235-245, 2000.***
40. **\*Mohamed L. Salem** and W. El Shouny. Exopolysaccharides produced by Pseudomonas syringae pathovars suppress tumor cell proliferation and augment thymocyte proliferation in vitro. ***Az. J. Pharm Sci 25: 175-188, 2000*.**
41. **\*Mohamed L. Salem** and Randa Ez Al Deen Al Nagar. Immunomodulatory and antitumor effects of simultaneous treatment of mice with n-3 and n-6 polyunsatrated fatty acids. ***J. Union Arab Biol, Vol. 14A:489-505, 2000.***
42. **\*Mohamed L. Salem** and Wael Y Attia. Synergestic effect of β-estradiol andprogesterone on the distribution of the immune cells in the lymphoid tissues. ***J. Union Arab Biol, Vol 14A:293-307, 2000.***
43. **\*Mohamed L. Salem**, Matsuzaki G., Gamal Madkour, and Nomoto K. β-estradiol-induced suppression of macrophages functions in the course of Listeria monocytogenes infection is mediated by suppression of IL-12 and TNF-alpha expression. ***Int. J. Immunopharm 21;487-497, 1999.***
44. **\*Mohamed L. Salem**. Increase of the bacteriostatic function against early infection of mice with Listeria monocytogenes after treatment with β-estradiol. ***J. Egypt German Society of Zoology, Vol.23(A), Comp. Physiol, 347-378, Feb. 1997.***
45. Wael Attia Y., Randa El-Naggar E., **Mohamed L. Salem**, and El-Bolkiny S. Influence of prolactin and prolactin antagonist, bromocriptine, on the regulation of the immune response. ***J. Egypt German Society of Zoology, Vol.23(A), Comp. Physiol., 325-346, Feb. 1997.***
46. El-Bolkiny E., **Mohamed L. Salem**, Wael Attia Y., and AL-Sharkawy I. Toxicological study of Ammi majus as a plant mollusccicide on the hemolysis and hemolysis-related parameters. ***J. Egypt German Society of Zoology, Vol.23 (A), Comp. Physiol. 379-3401, Feb. 1997.***
47. **\*Mohamed L. Salem**, Wael Attia Y., Wageh Awara A., Al Mehallawy A. Immunotoxicity of cadmium chloride in mice. ***J. Union Arab Biology, Vol. 6 (A) Zoology, 531-554, Nov. 1996.***
48. Fouad A. Abou-Zaid; Siham B. Salem and **Mohamed L. Salem**. Oesteology of *Psammomys obesus* I. *The cranial region.* ***Delta J. Sci. 13 (4): 2087-3002, 1989.***
49. Fouad A. Abou-Zaid; Siham B. Salem and **Mohamed L. Salem**. Oesteology of *Psammomys obesus*. II. *The post-cranial region.* ***Delta J. Sci. 13 (4): 3003-3024, 1989.***
50. Fouad A. Abou-Zaid; Siham B. Salem and **Mohamed L. Salem**. Histological studies on the digestive system of the fat sand rat *Psammomys obesus*. ***Delta J. Sci. 12 (2): 1141-1166, 1988.***

**Book Chapters**

1. C. Bryce Johnson, **Mohamed L Salem**, Shikhar Mehrotra, David J. Cole, and Mark P. Rubinstein: Tumours: Immunotherapy **(Version 3)**. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0001432.pub2]
2. **Mohamed L** **Salem**, Rubinstein, Mark P, and Cole, David J (Apr 2007) Tumours: Immunotherapy **(Version 2).** In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0001432.pub2]
3. **Mohamed L. Salem**: The potential use of autologous dendritic cells for peptide-based vaccination in cancer immunotherapy *in* Protocols for the modification and manipulation of dendritic cells, Section I. Direct Manipulation and Modification of the Immune System. ***Methods in Molecular Biology***. *Cancer Vaccines Methods and Protocols.* Humana Press, Springer, 2013.
4. **Salem, L.M.,** Gadalla K.; Fielding, B.C., Thorne, S.H.: *Gene therapy and virus-based cancer vaccines in: Cancer Immunology: Translational Medicine from Bench to Bedside, Springer 2013*

**Review Articles**

**\*,** Corresponding author

1. Alenzi FQ, **Mohamed L. Salem**, Alenazi FA, Wyse RK. [Cellular and molecular aspects of goodpasture syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/22218111) ***Iran J Kidney Dis. 2012 Jan;6(1):1-***
2. Faris Q Alenzi, Mohammed A Alsakran Altamimi, Omar Kujan, Bassel Tarakji, Waleed Tamimi, Omar Bagader, Ali Al-Shangiti, Abdulrahman B T Alanazi, Awwad K Alenezy, Farhan Al-Swailmi, Dhaifallah Aleniz, **Mohamed L Salem** and Richard KH Wyse. Antioxidant Properties of Nigella sativa. ***Journal of Molecular and Genetic Medicine***. 2013, Vol. 3: 1-5
3. Bernard A. Fox, Dolores J. Schendel, Lisa H. Butterfield, Steinar Aamda, et al,. Defining the Critical Hurdles in Cancer Immunotherapy. ***Journal of Translational Medicine 2011, 9:214. This is an international consortium review article of 105 authors.*** *I am co-author number 83.*
4. **Mohamed L. Salem**: Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of immunotherap*y.* ***Immunology Letter; Jun 30;137(1-2):9-14, 2011.***
5. **Mohamed L. Salem,** Marina Demcheva, William E. Gillanders, David J Cole and John N. Vournakis. Poly-*N*-acetyl glucosamine gel Matrix as a non-viral delivery vector for DNA-based vaccination*.* ***AntiCancer Research. 2010 Oct;30(10):3889-94*.**
6. \* **Mohamed L. Salem**, Maha EL-Demellawy, and Abdel Raouf Abou El-Azm: The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. ***Cellular Immunology 262 (2010) 96-104****.*
7. **\* Mohamed L. Salem**: The potential use of dendritic cell-based immunotherapy for treatment of pancreatic cancer. ***Immunology, Endocrine and Metabolic Agents in Medicinal in Medicinal Chemistry" (IEMAMC), 2009, Vol. 9(4): 191-202.***
8. **\* Mohamed L. Salem** and David J. Cole: Dendritic cell recovery post lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination. ***Cancer Immunology and Immunotherapy. 2010 Mar;59(3):341-353.***
9. **\* Mohamed L. Salem**, Faris Q. Al-Anzi, Narender Nath, Ali A. Al-Jabri, Jamal Arif, Iman M. El-Nashar, Iman El-Tounsi, and Richard N. Wyse: Plasticity of T cell differentiation: A double-edged sword for immune responses. ***Immunology, Endocrine and Metabolic Agents in Medicinal in Medicinal Chemistry (IEMAMC), Vol. 9(2): 90-105, 2009.***
10. Faris Q Alenzi, Mohammed W Al-Rabia, Badi Q Alenazi, Abdulla M Mubaraki, Mahmoud Lotfy, **Mohamed L. Salem**, Haris M Siddiqui, Jamal M Arif*,* Shamweel Ahmad, Ali A Al-Jabri, Richard K Wyse. Role of CTLA-4 in xenotransplantation. ***Pak J Physiol 2009;5(2):40-45***
11. **\* Mohamed L. Salem,** Faris Q. Alenzi, Iman M. El-Nashar, Iman EL-Tounsi and Richard N. Wyse: Teaching versus research dilemma in academia: A literature review. ***The BioMed Scientist (www.aabs-inc.org), Vol. 5, 2009: 6-9.***
12. Faris Q. AL-Enzi and **Mohamed L. Salem**. The Hematopoietic Stem Cells: Between Apoptosis and Self-renewal. ***Yale J. Biology Medicine 2009, 82:7-18.***
13. **\* Mohamed L. Salem** and David J Cole: TH1/TH2 Cytokine Fingerprinting for Probing Diseases: From the Bench to the Clinic. ***Journal of Medical Sciences 2008; 1(2): 61-67*.**
14. **\* Mohamed L. Salem**: Bridging scientific enterprise in developed and less developed countries: Ideas for improving Sciences in developing countries. ***The BioMed Scientist (www.aabs-inc.org), Vol. 3, 2007: 3-4.***
15. Faris Q. AL-Enzi and **\* Mohamed L. Salem**. Career preference among university's faculty: Literature review. ***Education Resources Information Center (ERIC), 2007.*** *eric.ed.gov/ERICWebPortal/recordDetail?accno=ED497697.*
16. **\* Mohamed L. Salem**, Andre Kadima, Sabry EL-Naggar, and William E. Gillanders, David J. Cole. Novel non-viral delivery approaches for IL-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. ***J. Interferon & Cytokine Research, 2006, 26(9): 593-608.***
17. **\* Mohamed L. Salem**, Immunomodulatory and immunotherapeutic properties of *Nigella sativa* L. seeds. ***Int. Immunopharmacology. 2005, Vol 5/13-14:1749-1770***
18. **\* Mohamed L. Salem**. Estrogen, A Double-edged Sword: Modulation of TH1- and TH2-mediated Inflammations by Differential Regulation of TH1/TH2 Cytokine Production. ***Current Drug Targets-Inflammation & Allergy, 3: 95-102, 2004.***
19. Grab J. Dennis, **Mohamed L. Salem**, J.Dumler, R. Bucala and N-H Lanners A role for the peripheral blood fibrocytes in leishmaniasis? ***Trends Parasitology, 20:12, 2003.***
20. Grab J. Dennis, **Mohamed L. Salem**, J. Chesney, R. Bucala and N-H Lanners: A Role for Peripheral Blood Fibrocytes in Lyme disease? ***Med Hypotheses. 59:1-10, 2002.***
21. Mark P Rubinstein, **Mohamed L. Salem**. The influence of primary antigen encounter on the generation of T-cell memory. ***Trends Immunology (News and Comment), 23, 3: 123-124, 2002.***